Lenalidomide Sandoz (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

• Multiple myeloma: reduces disease progression and improves survival in eligible patients.
• Myelodysplastic syndromes with del(5q): corrects ineffective hematopoiesis and reduces transfusion dependence.
• Mantle cell lymphoma: contributes to disease control as part of combination therapy in appropriate cases.

• Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, modifying its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory and direct anti‑tumor activities that inhibit proliferation of malignant plasma cells and other hematologic cancer cells. The altered signaling also enhances natural killer cell activity and modulates cytokine production, contributing to its therapeutic effect.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness or lack of energy.
• Diarrhea: loose stools occurring intermittently.
• Nausea: feeling of sickness or urge to vomit.
• Rash: mild skin eruptions or itching.
• Constipation: difficulty passing stools.
• Low blood counts: mild reductions in neutrophils, platelets or red cells.

Serious or Rare Side Effects

• Deep vein thrombosis: formation of blood clots in veins.
• Pulmonary embolism: blockage of lung arteries by clots.
• Severe neutropenia: markedly low neutrophil count increasing infection risk.
• Severe thrombocytopenia: dangerously low platelet levels leading to bleeding.
• Secondary malignancies: emergence of new cancers.
• Liver toxicity: significant elevation of liver enzymes or hepatitis.

When prescribing Lenalidomide, clinicians should observe several precautionary measures to minimize risks.

• Pregnancy risk: avoid use in pregnant women; ensure effective contraception.
• Thromboembolic risk: assess for clotting history and consider prophylactic anticoagulation.
• Renal impairment: adjust monitoring in patients with reduced kidney function.
• Hepatic dysfunction: evaluate liver function before initiation.
• Infection monitoring: watch for signs of infection due to neutropenia.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lenalidomide exposure.
• Anticoagulants (warfarin, DOACs): increase bleeding risk.
• Immunosuppressants: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors: may raise plasma levels.
• NSAIDs: add to gastrointestinal bleeding risk.
• Vaccines: live vaccines may be less effective.